Last reviewed · How we verify
Withdrawal of Spironolactone
At a glance
| Generic name | Withdrawal of Spironolactone |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (PHASE4)
- Therapy to Maintain Remission in Dilated Cardiomyopathy (NA)
- Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction (NA)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) (PHASE3)
- Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (PHASE4)
- Treatment of Intermediate-stage Hepatocellular Carcinoma (PHASE3)
- Treatment of Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Withdrawal of Spironolactone CI brief — competitive landscape report
- Withdrawal of Spironolactone updates RSS · CI watch RSS
- Asan Medical Center portfolio CI